Evidence map›Paper›PMID 42170260›Full record

ArticleTranslational lung cancer research2026

DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling.

Guo-Nian Zhu, Qian Zheng, Pan Yang, Xue-Fei He, Pan Tang, Cheng-Di Wang, Jun Tang, Wei-Min Li, Zhou-Feng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guo-Nian ZhuDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0003-3214-2946
Qian ZhengDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Pan YangDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Xue-Fei HeDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Pan TangDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Cheng-Di WangDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Jun TangDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Wei-Min LiDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0009-0005-6999-5821
Zhou-Feng WangDepartment of Pulmonary and Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-7881-1837

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) represents a major clinical challenge due to its high recurrence and metastasis rates, with the underlying molecular mechanisms yet to be fully elucidated. Despite therapeutic advances, the prognosis of recurrent LUAD remains dismal, creating an urgent demand for novel therapeutic targets. Preferentially expressed antigen in melanoma ( Methods: To explore the role of Results: Transcriptomic and clinical analyses revealed significant upregulation of Conclusions: Collectively, this study establishes a comprehensive mechanistic framework: DNA hypomethylation facilitates ZNF740 binding to the

Indexed as

DNA hypomethylationLung adenocarcinoma (LUAD)PI3K/AKT/mTOR pathwaypreferentially expressed antigen in melanoma (PRAME)ZNF740

Identifiers

PMID42170260
PMCPMC13186639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.